An interventional study of Performance test in Depression - Major Depressive Disorder and Overweight (BMI > 25), sponsored by University of Zurich. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by University of Zurich · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Overweight with a site in Switzerland — 7 open to participants now, 13 under way, 4 of them phase 3. Overweight · Switzerland.
Among the 38 studies in Overweight with a site in Switzerland, this one is the 6th largest by planned enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 35th registered.
3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.
Browse Overweight studies →7 of the 38 studies in Overweight with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University of Bern · Sites in Switzerland
Ages 25+
University Hospital, Geneva · Sites in Switzerland
Ages 45–60 · Women only
Vrije Universiteit Brussel · Sites in Switzerland, Belgium
Ages 18–65
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2004; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 78 across 3,142 interventional studies indexed under Overweight.
Median enrollment 76 across the 29 interventional studies, 40 across the 9 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 38 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 3 studies filed under Overweight — fewer than ten, so there is no comparison to draw.
6 of the studies in Overweight with a site in Switzerland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT06855784University Hospital, GenevaTime-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO) | 2027-03-01 |
| NCT06370845University Hospital, Basel, SwitzerlandABUNDANCE of A NATURAL ODOUR in HUMAN CEREBROSPINAL FLUID AFTER OLFACTORY EXPOSURE - the OLFO-Brain Study | 2027-08-31 |
| NCT07036692University of BernThe FaibaGo Study - Long-Term Weight Reduction Via Low-Threshold Intervention | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 38 studies in Overweight with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Depression is a common mental health condition that affects millions of people worldwide and is a leading cause of disability. Although current treatments can be effective, many patients do not fully recover or experience long-term improvement. This study aims to better understand how lifestyle factors such as physical activity and diet-related processes may influence biological mechanisms that could be linked to depression.
The study focuses on a natural cellular process called autophagy, which helps cells remove damaged components and maintain healthy function. Autophagy is influenced by energy availability in the body and may be affected by behaviors such as physical exercise and caloric restriction. Early evidence suggests that changes in autophagy may also be linked to mood regulation and depression, but this relationship is not yet well understood in humans.
In this exploratory study, we will investigate how physical activity influences autophagy and related metabolic and molecular processes in healthy adults. We will also examine whether these effects differ between individuals with different body weight and fitness levels, and between women and men.
A total of approximately 120 healthy adults aged 18 to 40 years will participate. Participants will be divided into four groups based on sex and body weight (normal weight or overweight). Each participant will attend study visits at the University Hospital Zurich and perform a standardized cycling exercise test under medical supervision.
During the exercise test, participants will perform a graded cycling protocol that gradually increases in intensity until exhaustion. We will collect small blood samples from a vein and from a fingertip at several time points before, during, and after exercise. Saliva samples will also be collected to measure stress-related hormones. Additional measurements include heart rate, breathing parameters, oxygen consumption, and physical performance.
Blood and saliva samples will be analyzed using advanced laboratory techniques to study changes in metabolism, immune signaling, hormones, gene activity, and markers related to autophagy. These analyses will help identify biological pathways that are activated by exercise and may be relevant to brain health and depression.
Participants will undergo medical screening before inclusion to ensure safety. Individuals with certain medical conditions or factors that could interfere with the study results will not be included. Participation is voluntary, and participants may withdraw at any time without consequences.
The study involves minimal risks associated with blood sampling and intense physical exercise, which will be performed under close medical supervision. The expected benefit is improved scientific understanding of how lifestyle-related biological processes may be linked to mental health, which could support the development of new preventive or therapeutic strategies for depression in the future.
Background and Rationale Depressive disorders are among the leading causes of disability worldwide and represent a major public health burden. Despite the availability of pharmacological and psychotherapeutic treatments, a substantial proportion of patients do not achieve full remission or experience relapse. Current antidepressant strategies primarily target monoaminergic systems and are often insufficient in addressing the biological heterogeneity of depression.
Emerging evidence suggests that metabolic regulation and cellular stress response pathways may play an important role in the pathophysiology of depression. In particular, associations between metabolic disorders (such as obesity and insulin resistance) and depressive symptoms indicate shared biological mechanisms. This has led to increasing interest in lifestyle-based interventions, including physical activity, dietary modification, and caloric restriction, as potential modulators of both metabolic and neuropsychiatric outcomes.
A central candidate mechanism linking metabolism and brain function is autophagy, a conserved cellular process responsible for the degradation and recycling of damaged proteins and organelles. Autophagy is tightly regulated by nutrient availability and energy status, primarily via the AMPK-mTOR signaling axis. It is activated under energy deprivation and suppressed under nutrient excess. Proper autophagic flux is essential for neuronal homeostasis, immune regulation, and cellular stress adaptation.
Preclinical and emerging clinical evidence suggests that impaired autophagy may be involved in psychiatric disorders, including depression. Furthermore, interventions such as physical exercise, caloric restriction, and certain pharmacological agents have been shown to modulate autophagy-related pathways. However, the direct measurement of autophagic flux in humans under physiological conditions remains methodologically challenging, and its relationship to exercise-induced metabolic and neurobiological changes is not fully understood.
This study aims to address this gap by investigating autophagy-related biological responses to acute physical exercise in humans using a multi-omics approach.
Objectives Primary Objective To investigate whether acute physical exercise induces measurable changes in autophagy-related pathways and associated metabolic, proteomic, transcriptomic, and hormonal markers in humans.
Secondary Objectives To characterize exercise-induced changes in systemic metabolism, inflammatory markers, and stress hormones.
To explore associations between fitness level, body mass index (BMI), and molecular responses to exercise.
To identify potential biomarkers of autophagy activation in peripheral blood and saliva.
To generate mechanistic hypotheses linking metabolic regulation, autophagy, and pathways relevant to mood disorders.
Study Design This is a single-center, exploratory human research study conducted at the University Hospital Zurich in collaboration with exercise physiology facilities.
The study uses a cross-sectional experimental design involving standardized acute exercise stimulation (cardiopulmonary exercise testing, CPET) combined with repeated biological sampling and multi-omics profiling.
Participants will be stratified into four groups based on sex and BMI:
Normal-weight women Normal-weight men Overweight women Overweight men All participants will perform a standardized incremental cycling exercise test under controlled laboratory conditions.
Study Population Approximately 120 healthy adults aged 18-40 years will be included. Participants will be selected based on predefined inclusion and exclusion criteria to ensure medical safety and reduce confounding variables such as chronic disease, medication use, psychiatric disorders, and hormonal influences (e.g., hormonal contraception or pregnancy in women).
Women will be tested during early follicular phase (cycle days 1-5) to minimize hormonal variability.
Study Procedures
Each participant will undergo:
The protocol includes:
15-minute warm-up phase at submaximal intensity Incremental ramp protocol until voluntary exhaustion
Continuous monitoring of:
Oxygen uptake (VO₂) Carbon dioxide production (VCO₂) Heart rate and ECG Blood pressure Respiratory exchange ratio
Key physiological thresholds will be determined:
Aerobic threshold Anaerobic threshold Respiratory compensation point 4. Biological Sampling
Repeated biological sampling will be performed at defined time points:
Rest (baseline) End of warm-up (aerobic phase) Peak exercise (maximal exertion) 10 minutes recovery 30 minutes recovery
Samples include:
Venous blood (PBMC isolation and plasma) Capillary blood microsamples (fingertip sampling devices) Saliva (cortisol analysis) Urine (pregnancy test in women) Total blood volume per participant will be approximately 320 mL across all time points.
Laboratory Analyses
Collected samples will be used for multi-layered molecular profiling:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Performance test
Procedure: Performance test
Procedure: Performance test
Procedure: Performance test
Standardized CPET on a bicycle ergometer. Venous and capillary blood sampling at baseline (rest), end of aerobic warm-up phase (15 min), peak exercise (ramp-protocoll, 8-12 min), 10 minutes post-exercise, and 30 minutes post-exercise.
Autophagic Flux in Peripheral Blood Mononuclear Cells (PBMCs)
Assessment of autophagic flux in PBMCs using ex vivo lysosomal inhibition and quantification of autophagy-related proteins (e.g., LC3B-II) to evaluate exercise-induced activation of autophagy pathways.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise (single study day).
PBMC Transcriptome
Genome-wide transcriptomic profiling of PBMCs using RNA sequencing to identify exercise-induced changes in gene expression and cellular signaling pathways.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
PBMC Proteome
Untargeted proteomic analysis of PBMCs to characterize exercise-induced changes in protein abundance and biological pathways.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
PBMC Phosphoproteome
Untargeted phosphoproteomic profiling of PBMCs to assess exercise-induced changes in intracellular signaling and protein phosphorylation.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Plasma Proteome
Untargeted plasma proteomics to identify circulating proteins and pathways altered by acute physical exercise.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Targeted Plasma Metabolomics
Quantification of metabolites involved in energy metabolism, autophagy regulation, oxidative stress, and exercise adaptation using targeted metabolomic approaches.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Untargeted Metabolomic Profile
Comprehensive metabolomic profiling to identify exercise-induced changes in metabolic pathways associated with autophagy, energy homeostasis, and stress responses.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Polyamine Concentrations
Quantification of circulating polyamines and related metabolites, including spermidine-associated pathways implicated in autophagy regulation.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Steroid Hormone Profile
Measurement of circulating steroid hormones, including cortisol, cortisone, DHEA, DHEAS, progesterone, estradiol, testosterone, aldosterone, and related metabolites using mass spectrometry.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Inflammatory Marker Profile
Quantification of circulating inflammatory cytokines and immune mediators, including IL-1α, IL-4, IL-6, IL-10, IL-13, and TNF-α.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Genome-wide DNA Oxidation Profile
Genome-wide mapping of oxidative DNA lesions in PBMCs to assess exercise-induced oxidative stress and genomic responses.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Genome-wide DNA Strand Break Profile
Genome-wide assessment of DNA strand breaks in PBMCs to characterize genomic stress responses induced by acute exercise.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
DNA Methylation Profile
Genome-wide DNA methylation analysis to investigate exercise-induced epigenetic regulation and associations with transcriptional responses.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Extracellular Vesicle Profile
Characterization of circulating extracellular vesicles and their molecular cargo as potential mediators of exercise-induced intercellular communication.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Cardiorespiratory Fitness (VO₂max)
Maximum oxygen uptake measured during cardiopulmonary exercise testing as an indicator of aerobic fitness and exercise capacity.
Time frame: Measured during the exercise test on the study day.
Blood Lactate Concentration
Capillary blood lactate concentrations measured during exercise to assess metabolic responses and anaerobic metabolism.
Time frame: Baseline (rest), end of aerobic warm-up phase, and peak exercise.
Body Composition
Assessment of body fat mass, lean mass, and bone mineral density using dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline assessment prior to exercise testing.
Depressive Symptoms (Beck Depression Inventory-II, BDI-II)
Assessment of depressive symptom severity using the Beck Depression Inventory-II (BDI-II), a validated self-report questionnaire.
Time frame: Baseline (Visit 1, prior to exercise testin
Anxiety Symptoms (State-Trait Anxiety Inventory, STAI)
Assessment of state and trait anxiety using the State-Trait Anxiety Inventory (STAI).
Time frame: Baseline (Visit 1, prior to exercise testing).
Physical Activity Level (International Physical Activity Questionnaire, IPAQ)
Assessment of habitual physical activity and exercise behavior using the International Physical Activity Questionnaire (IPAQ).
Time frame: Baseline (Visit 1, prior to exercise testing).
Positive and Negative Affect (PANAS)
Assessment of positive and negative affective states using the Positive and Negative Affect Schedule (PANAS).
Time frame: Immediately before exercise testing and 30 minutes after completion of exercise testing.
Mood States (Profile of Mood States, POMS)
Assessment of transient mood states, including tension, depression, anger, vigor, fatigue, and confusion, using the Profile of Mood States (POMS).
Time frame: Immediately before exercise testing and 30 minutes after completion of exercise testing.
Subjective Well-Being (Befindlichkeitsskalen, BF)
Assessment of current subjective well-being and psychological state using the Befindlichkeitsskalen (BF).
Time frame: Immediately before exercise testing and 30 minutes after completion of exercise testing.
Current Psychological State (Eigenzustandsskala, EZ)
Assessment of participants' current psychological state using the Eigenzustandsskala (EZ).
Time frame: Immediately before exercise testing and 30 minutes after completion of exercise testing.
Premenstrual Symptoms (PMS Questionnaire)
Assessment of menstrual cycle-related symptoms in female participants using a standardized Premenstrual Syndrome (PMS) questionnaire.
Time frame: Baseline (Visit 1, female participants only).
Capillary Blood Microsampling
Evaluation of two certified capillary blood microsampling systems (Mitra® device and Whatman® 903 Protein Saver cards) for the collection of capillary blood samples. Comparisons will assess sample quality, analytical performance, feasibility, and concordance of omics-based measurements obtained from microsamples across repeated exercise-associated sampling time points.
Time frame: Baseline (rest), end of aerobic warm-up phase, peak exercise, 10 minutes post-exercise, and 30 minutes post-exercise.
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in publications may be shared with qualified researchers for scientific research purposes. Shared data may include demographic, physiological, questionnaire, laboratory, and multi-omics datasets collected as part of the study. The study protocol, statistical analysis plan, informed consent form, and data dictionary may also be made available. Data will be available beginning 12 months after publication of the primary study results and for up to 10 years thereafter. Access will be granted upon reasonable request, following review and approval of a scientifically sound research proposal by the study investigators and sponsoring institution. Any data sharing will be subject to approval by the responsible ethics committee, where required, and compliance with applicable data protection regulations. Data sharing will further require execution of an appropriate data sharing or transfer agreement to ensure partici
Supporting information: Study protocol, Statistical analysis plan
Time frame: 12 months after publication until 10 years after publication
Access criteria: Upon reasonable request and approval
Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.
Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 36 months is above that.
Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.